Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta‐analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion

Aims  Continuous subcutaneous insulin infusion (CSII) is a recommended treatment for reducing severe hypoglycaemia in Type 1 diabetes, but the change in hypoglycaemia compared with multiple daily insulin injections (MDI) is unclear. We therefore conducted a meta‐analysis comparing severe hypoglycaemia and glycaemic control during CSII and MDI.

[1]  A. Berghold,et al.  Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis , 2008, Diabetologia.

[2]  Ian Shrier,et al.  Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. , 2007, American journal of epidemiology.

[3]  Wolfgang Viechtbauer,et al.  Publication bias in meta-analysis: Prevention, assessment and adjustments , 2007, Psychometrika.

[4]  G. J. Ebrahim,et al.  Publication bias in Meta-Analysis: prevention, assessment and adjustments Hannah R. Rothstein, Alexander J. Sutton, Michael Borenstein (eds) Chichester, John Wiley & Sons Ltd. 2005. ISBN 0–470–870–141 £55 , 2006 .

[5]  J. Pickup,et al.  Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability , 2006, Diabetes/metabolism research and reviews.

[6]  D. Bruttomesso,et al.  Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH‐based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5‐nations trial , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[7]  K. Ismail,et al.  Indications and efficacy of continuous subcutaneous insulin infusion (CSII) therapy in Type 1 diabetes mellitus: a clinical audit in a specialist service , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[8]  R. Trevisan,et al.  Age and A1C are important clinical predictors of continuous subcutaneous insulin infusion efficacy in type 1 diabetic patients. , 2005, Diabetes care.

[9]  R. Schiaffini,et al.  An observational study comparing continuous subcutaneous insulin infusion (CSII) and insulin glargine in children with type 1 diabetes , 2005, Diabetes/metabolism research and reviews.

[10]  A. Berghold,et al.  Systematic Review and Meta-analysis of Short-Acting Insulin Analogues in Patients With Diabetes Mellitus , 2006 .

[11]  Workgroup on Hypoglycemia.  Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. , 2005, Diabetes care.

[12]  N. Jospe,et al.  Continuous subcutaneous insulin infusion in toddlers and children with type 1 diabetes mellitus is safe and effective , 2005, Pediatric diabetes.

[13]  I. Hirsch,et al.  Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. , 2005, Diabetes care.

[14]  T. Jones,et al.  Insulin pump therapy in children and adolescents: improvements in key parameters of diabetes management including quality of life , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[15]  J. Pickup,et al.  Effectiveness of continuous subcutaneous insulin infusion in hypoglycaemia‐prone type 1 diabetes , 2005 .

[16]  S. Nordfeldt,et al.  Fear and Other Disturbances of Severe Hypoglycaemia in Children and Adolescents with Type 1 Diabetes Mellitus , 2005, Journal of pediatric endocrinology & metabolism : JPEM.

[17]  Workgroup on Hypoglycemia.  Defining and Reporting Hypoglycemia in Diabetes , 2005 .

[18]  W. Tamborlane,et al.  Persistence of Benefits of Continuous Subcutaneous Insulin Infusion in Very Young Children With Type 1 Diabetes: A Follow-up Report , 2004, Pediatrics.

[19]  K. Herold,et al.  Continuous subcutaneous insulin infusion in older patients with type 1 diabetes. , 2004, Diabetes care.

[20]  P Wainwright,et al.  Virtual outreach: a randomised controlled trial and economic evaluation of joint teleconferenced medical consultations. , 2004, Health technology assessment.

[21]  A. Berghold,et al.  Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy , 2004, Diabetologia.

[22]  Philip Hougaard,et al.  Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection , 2004, Diabetes/metabolism research and reviews.

[23]  B. Zinman,et al.  Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. , 2004, Diabetes care.

[24]  C. Beverley,et al.  Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. , 2004, Health technology assessment.

[25]  W. Kiess,et al.  Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes. , 2004, Diabetes care.

[26]  T. Jones,et al.  The impact of a decade of changing treatment on rates of severe hypoglycemia in a population-based cohort of children with type 1 diabetes. , 2004, Diabetes care.

[27]  W. Tamborlane,et al.  A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. , 2004, Diabetes care.

[28]  E. Parton,et al.  Beneficial effects of continuous subcutaneous insulin infusion and flexible multiple daily insulin regimen using insulin glargine in type 1 diabetes. , 2004, Pediatrics.

[29]  D. Russell-Jones,et al.  Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. , 2004, Clinical therapeutics.

[30]  P. Home,et al.  Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. , 2004, Diabetes care.

[31]  K. Hermansen,et al.  Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes , 2004, Diabetologia.

[32]  G. Talavera,et al.  Improvement in diabetes care of underinsured patients enrolled in project dulce: a community-based, culturally appropriate, nurse case management and peer education diabetes care model. , 2004, Diabetes care.

[33]  U. Müller,et al.  Insulin pump therapy in patients with Type 1 diabetes mellitus: results of the Nationwide Quality Circle in Germany (ASD) 1999-2000. , 2003, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[34]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[35]  Moshe Phillip,et al.  Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. , 2003, Pediatrics.

[36]  P. Cryer,et al.  Hypoglycemia in diabetes. , 2003, Diabetes care.

[37]  J. Weissberg-Benchell,et al.  Insulin pump therapy: a meta-analysis. , 2003, Diabetes care.

[38]  T. Erlinger,et al.  Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. , 2003, Diabetes care.

[39]  W. Herman.  Glycaemic control in diabetes , 1999, Clinical evidence.

[40]  M. Phillip,et al.  Continuous Subcutaneous Insulin Infusion versus Multiple Daily Injections in Adolescents with Type I Diabetes Mellitus: A Randomized Open Crossover Trial , 2003, Journal of pediatric endocrinology & metabolism : JPEM.

[41]  I. Hirsch,et al.  Assessment of therapy with continuous subcutaneous insulin infusion in an academic diabetes clinic. , 2002, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[42]  M. Freemark,et al.  Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. , 2002, The Journal of pediatrics.

[43]  M. Berger,et al.  Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[44]  E. Casiglia,et al.  Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and quality of life , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[45]  John Pickup,et al.  Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials , 2002, BMJ : British Medical Journal.

[46]  Douglas G Altman,et al.  Meta-analyses involving cross-over trials: methodological issues. , 2002, International journal of epidemiology.

[47]  F. Capani,et al.  COMPARISON OF A MULTIPLE DAILY INJECTION REGIMEN WITH ONCE-DAILY INSULIN GLARGINE BASAL INSULIN AND MEALTIME LISPRO, TO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION: A RANDOMIZED, OPEN, PARALLEL STUDY , 2002 .

[48]  M. Arnold,et al.  Beneficial effects of continuous subcutaneous insulin infusion in older patients with long-standing type 1 diabetes. , 2001, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[49]  H. Chase,et al.  Continuous subcutaneous insulin infusion therapy for children and adolescents: an option for routine diabetes care. , 2001, Pediatrics.

[50]  T Stijnen,et al.  Baseline risk as predictor of treatment benefit: three clinical meta-re-analyses. , 2000, Statistics in medicine.

[51]  S G Thompson,et al.  Analysing the relationship between treatment effect and underlying risk in meta-analysis: comparison and development of approaches. , 2000, Statistics in medicine.

[52]  P. Raskin,et al.  A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. , 2000, Diabetes care.

[53]  W. Tamborlane,et al.  Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. , 1999, Diabetes care.

[54]  S. Sharp,et al.  Explaining heterogeneity in meta-analysis: a comparison of methods. , 1997, Statistics in medicine.

[55]  A. Kanatsuka,et al.  Continuous Subcutaneous Insulin Infusion , 1998, Diabetes Care.

[56]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[57]  P. Davidson,et al.  Reduction in Severe Hypoglycemia With Long-Term Continuous Subcutaneous Insulin Infusion in Type I Diabetes , 1996, Diabetes Care.

[58]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[59]  E. Helve,et al.  Insulin pump therapy , 1988 .